Invention Grant
US08236804B2 Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
有权
1-（4-氰基吲哚-3-基）丁基-4-（2-氨基甲酰基苯并呋喃-5-基）哌嗪盐酸盐的多晶型
- Patent Title: Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
- Patent Title (中): 1-（4-氰基吲哚-3-基）丁基-4-（2-氨基甲酰基苯并呋喃-5-基）哌嗪盐酸盐的多晶型
-
Application No.: US13100948Application Date: 2011-05-04
-
Publication No.: US08236804B2Publication Date: 2012-08-07
- Inventor: Andreas Bathe , Bernd Helfert , Steffen Neuenfeld , Heike Kniel , Matthias Bartels , Susanne Rudolph , Henning Böttcher
- Applicant: Andreas Bathe , Bernd Helfert , Steffen Neuenfeld , Heike Kniel , Matthias Bartels , Susanne Rudolph , Henning Böttcher
- Applicant Address: DE Darmstadt
- Assignee: Merck Patentgesellschaft
- Current Assignee: Merck Patentgesellschaft
- Current Assignee Address: DE Darmstadt
- Agency: McCarter & English, LLP
- Priority: EP01113647 20010619
- Main IPC: A61K31/496
- IPC: A61K31/496 ; C07D401/14
Abstract:
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
Public/Granted literature
Information query
IPC分类:
